
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News
- Épisodes
- 17
- Parution
- quotidienne
- Dernier épisode
- 15 Nov 2026
À propos du podcast
One GLP-1 story a day, sourced and explained. GLP-1 Newspaper covers the biggest daily news on weight-loss and diabetes drugs like Ozempic, Wegovy, Zepbound, Mounjaro, and new ones like retatrutide, orforglipron, and the Wegovy pill. Each short episode breaks down one story, such as an FDA decision, new trial results, price and insurance changes, shortages, or safety updates. We cover what happened, what it means for patients, and what we don't know yet. Every episode links to its primary sources, like FDA notices, clinical trial records, journals, and company announcements, at glp1newspaper.com.
For information only, not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Licence : © 2026 GLP-1 Newspaper. All rights reserved.
Épisodes 17
Novo's CagriSema Cut Weight About 21% at Two Lower Doses in Phase 3 REDEFINE 9 Trial
Novo Nordisk reported full results from REDEFINE 9, the first Phase 3 weight-management trial of its investigational once-weekly injection CagriSema (a fixed-dose combination of the amylin analog cagrilintide …
Notes de l’épisode
Novo Nordisk reported full results from REDEFINE 9, the first Phase 3 weight-management trial of its investigational once-weekly injection CagriSema (a fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide) at two doses below the 2.4 mg/2.4 mg dose used across the rest of the REDEFINE program. The results were announced on November 14, 2026, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology. The 68-week trial randomized 309 adults with obesity, or overweight with at least one obesity-related complication, and without diabetes, at 24 sites in Canada, France, Germany, the UK and the US. Each dose was compared with pooled placebo, and the trial was not powered to compare the two doses with each other. If everyone stayed on treatment, average weight loss was 20.7% with CagriSema 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo; counting everyone regardless of stopping treatment, it was 19.4% and 18.6% versus 4.6%. Most side effects were mild to moderate and gastrointestinal; 2.9% and 4.9% stopped treatment because of adverse events, versus 4.9% on placebo, and no deaths were reported. CagriSema is not approved in the US. Novo filed with the FDA in December 2025 for the 2.4 mg/2.4 mg dose for weight management and expects a decision in the fourth quarter of 2026. The trial was funded by Novo Nordisk.
Sources
- Novo Nordisk press release (Nov 14, 2026), CagriSema demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial: prnewswire.com
- The Lancet Diabetes & Endocrinology (Nov 14, 2026), Wharton S, et al., Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9): doi.org (abstract on PubMed)
- ObesityWeek 2026 abstract, Poster-344, REDEFINE 9: Effect of CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg in Adults with Overweight or Obesity: planion.events
- ClinicalTrials.gov, NCT06388187 (REDEFINE 9): clinicaltrials.gov
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
China Approves Lilly's Orforglipron Pill for Weight Management, the First Oral GLP-1 Cleared There for That Use
China's National Medical Products Administration has approved Eli Lilly's once-daily oral GLP-1 pill orforglipron, sold as Foundayo in the US and UK and as Muyouda in China, for long-term weight management …
Notes de l’épisode
China's National Medical Products Administration has approved Eli Lilly's once-daily oral GLP-1 pill orforglipron, sold as Foundayo in the US and UK and as Muyouda in China, for long-term weight management, with the approval announced on November 12, 2026. It is the first oral GLP-1 approved for weight management in China, where only injectable GLP-1s had been approved for that use. The approval covers adults with a starting BMI of 30 or more, or 27 to under 30 with at least one weight-related condition such as high blood pressure, abnormal blood lipids, high blood sugar, obstructive sleep apnea or cardiovascular disease, alongside a reduced-calorie diet and more physical activity. A separate application for type 2 diabetes is still under review in China. Lilly has not disclosed a price or launch date and says it will supply the drug through authorized healthcare and pharmaceutical institutions. In the Lilly-funded ATTAIN-1 Phase 3 trial of 3,127 adults with obesity and without diabetes, published in the New England Journal of Medicine, average weight change at 72 weeks was -7.5%, -8.4% and -11.2% in the three orforglipron groups versus -2.1% with placebo; gastrointestinal side effects were the most common and mostly mild to moderate, and 5.3% to 10.3% stopped treatment because of adverse events versus 2.7% on placebo.
Sources
- China National Medical Products Administration approval notice (Nov 12, 2026), orforglipron calcium tablets, reprinted by China Pharmaceutical News (Chinese): cnpharm.com
- Lilly China press release (Nov 12, 2026), Muyouda (orforglipron) approved (Chinese): lilly.com.cn
- New England Journal of Medicine, Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1), abstract on PubMed: pubmed.ncbi.nlm.nih.gov
- Reuters via U.S. News (Nov 12, 2026), Eli Lilly Becomes First Drugmaker to Have a GLP-1 Weight-Loss Pill Approved in China: money.usnews.com
- Fierce Pharma regulatory tracker (Nov 12, 2026), Lilly beats Novo to land China's 1st oral GLP-1 weight loss nod: fiercepharma.com
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
CDC Survey: About 1 in 10 U.S. Adults Used a GLP-1 in 2025, and 44% of Users Changed How They Took It
A new CDC report published November 12, 2026, in the Morbidity and Mortality Weekly Report looks at how U.S. adults used GLP-1 medications in 2025. In a national survey of 8,118 adults through CDC's Rapid …
Notes de l’épisode
A new CDC report published November 12, 2026, in the Morbidity and Mortality Weekly Report looks at how U.S. adults used GLP-1 medications in 2025. In a national survey of 8,118 adults through CDC's Rapid Surveys System, collected in July and August 2025, about one in 10 adults (9.8%) reported taking a GLP-1 medication in the past year, including 47.4% of adults who reported ever having diabetes. Among the 976 users, 22.6% reported taking a compounded version and another 8.8% did not know whether theirs was compounded. Forty-four percent said they had modified their use from the way it was prescribed, most often by skipping doses (28%). Modification was more common among adults 18 to 39 than among those 65 and older (54% vs 30%) and among compounded-drug users than other users (62% vs 36%). Among those who modified their use, 38% cited cost and 36% availability; about 12% of all users reduced or stopped because of side effects or symptoms. The CDC notes that compounded GLP-1 medications are not reviewed by the FDA for safety, effectiveness or quality before they are marketed, and that the findings are self-reported, from online panels with low response rates.
Sources
- CDC Morbidity and Mortality Weekly Report (Nov 12, 2026), Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025: cdc.gov
- CDC National Center for Health Statistics, Rapid Surveys System Round 7 datasets and documentation: cdc.gov
- U.S. Food and Drug Administration, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize: fda.gov
- Ars Technica (Nov 13, 2026), Millions of Americans are not taking their GLP-1 drugs as prescribed: arstechnica.com
- Quartz (Nov 13, 2026), Nearly half of U.S. weight-loss drug users are changing how they take them, CDC finds: qz.com
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Boehringer's Survodutide Did Not Raise Heart Risk in a 5,530-Person Phase 3 Safety Trial, as Boehringer Moves Toward Obesity Filings
Boehringer Ingelheim's investigational weekly injection survodutide, a glucagon/GLP-1 dual agonist, did not increase the risk of major heart and blood-vessel events compared with placebo in the Phase 3 …
Notes de l’épisode
Boehringer Ingelheim's investigational weekly injection survodutide, a glucagon/GLP-1 dual agonist, did not increase the risk of major heart and blood-vessel events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial, presented at the American Heart Association's Scientific Sessions 2026 and published in The Lancet on November 9, 2026. The cardiovascular safety trial enrolled 5,530 adults with overweight or obesity and heart disease, chronic kidney disease, or at least two weight-related risk factors. The main combined endpoint (cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary revascularization or heart failure event) occurred in 3.7% of people on survodutide and 4.1% on placebo (hazard ratio 0.89, 95% CI 0.67 to 1.18), meeting the goal of showing no increase in risk; the trial was not designed to show a heart benefit. Under the supplementary estimand at 72 weeks, weight fell by up to 13.7% versus 2.0% with placebo, systolic blood pressure by up to 6.68 versus 1.76 mmHg, and waist size by up to 11.96 versus 2.74 cm. Nausea and vomiting were far more common on survodutide, and 19.3% and 20.8% of people in the two survodutide arms stopped treatment because of gastrointestinal side effects, versus 1.9% on placebo; serious adverse events were similar across groups. Survodutide is not approved anywhere. Boehringer, which funded the trial, says it is moving toward regulatory submissions in obesity and told Fierce Biotech it aims to file for weight loss in the next year.
Sources
- Boehringer Ingelheim press release (Nov 9, 2026), survodutide SYNCHRONIZE-CVOT results: globenewswire.com
- The Lancet (Nov 9, 2026), Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT), abstract on PubMed: pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov, NCT06077864 (SYNCHRONIZE-CVOT): clinicaltrials.gov
- Fierce Biotech (Nov 9, 2026), AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test: fiercebiotech.com
- AJMC (Nov 9, 2026), Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT: ajmc.com
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Lilly's Foundayo Pill Reduced Sleep Apnea Severity in Two Phase 3 Trials, With an FDA Filing Planned by Year-End
Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) reduced the severity of obstructive sleep apnea in its Phase 3 ATTAIN-OSA program, presented at the American Heart Association's Scientific Sessions …
Notes de l’épisode
Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) reduced the severity of obstructive sleep apnea in its Phase 3 ATTAIN-OSA program, presented at the American Heart Association's Scientific Sessions 2026 and published in JAMA on November 9, 2026. The program included two 52-week, placebo-controlled trials in 712 adults with moderate-to-severe sleep apnea and overweight or obesity, without diabetes: 363 people not using positive airway pressure (PAP/CPAP) therapy and 349 who were using it. In the JAMA paper's primary analysis, breathing interruptions (the apnea-hypopnea index) fell by 17.8 events per hour with orforglipron versus 4.5 with placebo in people not using PAP, and by 17.3 versus 5.3 in people using PAP. Lilly's efficacy-estimand figures show a 43.8% and 27.5% reduction, with 31.5% and 19.6% reaching remission or mild disease, plus about 11% weight loss and lower oxygen-drop burden, inflammation and blood pressure. Gastrointestinal side effects were most common, and more people stopped treatment because of side effects on orforglipron. Foundayo is approved in the US for weight management only, not for sleep apnea; Lilly plans to submit it to the FDA for sleep apnea by the end of 2026. Zepbound is the Lilly drug already approved for moderate-to-severe sleep apnea in adults with obesity. The trials lasted one year, excluded people with diabetes, and were funded by Lilly.
Sources
- Eli Lilly and Company press release (Nov 9, 2026), Foundayo (orforglipron) ATTAIN-OSA results: investor.lilly.com
- JAMA (Nov 9, 2026), Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA): jamanetwork.com
- American Heart Association news release (Nov 9, 2026), Daily, oral GLP-1 medication reduced episodes of sleep apnea in adults with excess weight: newsroom.heart.org
- ClinicalTrials.gov, NCT06649045 (ATTAIN-OSA): clinicaltrials.gov
- Fierce Pharma (Nov 9, 2026), Lilly looks to gird Foundayo label after late-stage win in sleep apnea: fiercepharma.com
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
FDA Requires a Warning About Rare Vision Loss (NAION) on All GLP-1 Drugs, From Ozempic and Wegovy to Mounjaro and Zepbound
On November 9, 2026, the US Food and Drug Administration said it is requiring the makers of all GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo, to add …
Notes de l’épisode
On November 9, 2026, the US Food and Drug Administration said it is requiring the makers of all GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo, to add information to the Warnings and Precautions section of their labels about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent vision loss. In an FDA analysis of 126 randomized trials with 134,253 patients, there were 10 probable NAION cases among people on GLP-1 drugs and 5 among people on placebo, or 6.4 versus 3.8 cases per 100,000 person-years. An FDA Sentinel study in adults with type 2 diabetes found a higher risk with GLP-1 drugs than with DPP-4 inhibitors but no statistically significant difference compared with SGLT2 inhibitors, and FDA's review of animal data did not identify a mechanism. FDA describes the risk as potential. We also cover the 2024 JAMA Ophthalmology study that prompted FDA's review, the European Medicines Agency's June 2025 conclusion that NAION is a very rare side effect of semaglutide, and statements from Novo Nordisk and Eli Lilly.
Sources
- FDA Drug Safety Communication (Nov 9, 2026), labeling changes for GLP-1 receptor agonists due to potential increased risk of NAION: fda.gov
- Reuters (Nov 9, 2026), US FDA orders new eye risk warnings for Ozempic, Zepbound: investing.com
- Bloomberg (Nov 9, 2026), FDA adds warning label to obesity drugs for eye condition, with Novo Nordisk and Lilly statements: ndtvprofit.com
- Healio (Nov 9, 2026), FDA to require NAION risk warning for GLP-1 therapies: healio.com
- European Medicines Agency (June 6, 2025), PRAC concludes NAION is a very rare side effect of semaglutide medicines: ema.europa.eu
- JAMA Ophthalmology (2024), Hathaway et al., risk of NAION in patients prescribed semaglutide (PubMed abstract): pubmed.ncbi.nlm.nih.gov
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Semaglutide Lowered Heart Filling Pressures in a Small Obesity-Related Heart Failure Trial, Plus New Tirzepatide MRI Data From SUMMIT
Two new sets of heart-failure data on GLP-1-based drugs were presented at the American Heart Association's Scientific Sessions 2026 in Chicago on November 8, 2026. In CAMEO-SEMA, a Mayo Clinic-led, double-blind …
Notes de l’épisode
Two new sets of heart-failure data on GLP-1-based drugs were presented at the American Heart Association's Scientific Sessions 2026 in Chicago on November 8, 2026. In CAMEO-SEMA, a Mayo Clinic-led, double-blind trial published in Nature Medicine, 81 adults with obesity and heart failure with preserved ejection fraction (HFpEF) were randomized to semaglutide 2.4 mg weekly or placebo for 52 weeks. Pressure inside the left side of the heart during low-intensity exercise, measured by catheter, fell by an average of 9.8 mmHg on semaglutide and rose 0.9 mmHg on placebo (a difference of 10.6 mmHg), resting pressure also fell more, and 53.7% of people on semaglutide versus 7.4% on placebo had normal pressures at rest and during exercise at 52 weeks. A 49-person MRI substudy reported improvements in left atrial function and heart filling. We also cover a new three-dimensional MRI analysis from Lilly's tirzepatide SUMMIT trial, which found that left atrial volume and right ventricular mass decreased compared with placebo. These are small studies of pressure and imaging measures, not hospitalizations or deaths, the reports we have do not include side-effect data, and the two drugs were not compared with each other.
Sources
- Nature Medicine (Nov 8, 2026), Borlaug et al., hemodynamic effects of semaglutide in HFpEF and obesity (CAMEO-SEMA): nature.com
- Nature Medicine (Nov 8, 2026), Ghanbari et al., CAMEO-SEMA cardiac MRI substudy: nature.com
- ClinicalTrials.gov, NCT05371496 (CAMEO-SEMA): clinicaltrials.gov
- Radcliffe Cardiology (Nov 8, 2026), SUMMIT: tirzepatide and cardiac remodelling in HFpEF, interview with Dr. Milton Packer: radcliffeckm.com
- American College of Cardiology (Nov 16, 2024), original SUMMIT results: acc.org
- American Heart Association, Scientific Sessions 2026 late-breaking science program: professional.heart.org
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Novo Real-World Studies Link Wegovy to Lower Liver Enzymes and Weight in MASH, Presented at The Liver Meeting 2026
Novo Nordisk presented two real-world studies of Wegovy (semaglutide 2.4 mg) in adults with MASH at The Liver Meeting 2026 (AASLD) in Denver on November 6, 2026. In PLATINUM-Truveta, 2,873 adults who started …
Notes de l’épisode
Novo Nordisk presented two real-world studies of Wegovy (semaglutide 2.4 mg) in adults with MASH at The Liver Meeting 2026 (AASLD) in Denver on November 6, 2026. In PLATINUM-Truveta, 2,873 adults who started semaglutide were compared with 2,285 who started resmetirom (Rezdiffra). At six months, semaglutide was associated with larger reductions in weight (18.9 lb vs 5.6 lb), AST and HbA1c; the ALT difference was not statistically significant, and LDL fell more with resmetirom. In RHODIUM-2, 2,479 semaglutide starters were compared with 70,702 people with MASH who did not start it, with larger 12-month reductions in ALT, AST and weight. Both studies were retrospective and observational: they show associations, not cause and effect, and they measured blood markers and weight, not liver scarring or clinical outcomes. We put the new data next to what the randomized ESSENCE trial showed and what FDA's August 2025 accelerated approval of Wegovy for MASH requires, with ESSENCE's 240-week outcome results still pending.
Sources
- Novo Nordisk press release (Nov 6, 2026), PLATINUM-Truveta and RHODIUM-2 results: prnewswire.com
- Novo Nordisk U.S. press release (Oct 28, 2026), Liver Meeting 2026 abstract slate: novonordisk-us.com
- U.S. FDA (Aug 15, 2025), FDA Approves Treatment for Serious Liver Disease Known as 'MASH': fda.gov
- EconoTimes (Nov 7, 2026): econotimes.com
- Peptide Policy Watch (Nov 5, 2026, updated Nov 7), ESSENCE and the Denver program: peptidepolicywatch.com
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Lilly and Hims & Hers Offer Zepbound and Foundayo at Self-Pay Prices Starting at $149 and $299
Eli Lilly and Hims & Hers announced an agreement on November 6, 2026, to expand access to FDA-approved Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers telehealth platform. Eligible …
Notes de l’épisode
Eli Lilly and Hims & Hers announced an agreement on November 6, 2026, to expand access to FDA-approved Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers telehealth platform. Eligible patients who receive a prescription from a licensed provider on the platform can get the medicines at Lilly's self-pay prices without leaving the platform, with home shipment after consultation. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound. Hims & Hers has never offered compounded copies of Lilly's GLP-1s and committed not to do so; the companies also said they will protect independent clinical decision-making. The arrangement puts Lilly on similar footing with Novo Nordisk's earlier branded-access deal with Hims & Hers.
Sources
- Eli Lilly IR joint release (Nov 6, 2026): investor.lilly.com
- Reuters via U.S. News Money (Nov 6, 2026): money.usnews.com
- BioPharma Dive (Nov 6, 2026): biopharmadive.com
- pharmaphorum (Nov 6, 2026): pharmaphorum.com
- BariatricPal / Obesity Treatment News brief: bariatricpal.com
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Lilly Oral Orforglipron Beat Placebo on Weight Loss in Japan ATTAIN-J Phase 3, With 12 mg Leading Numerically
Eli Lilly's once-daily oral GLP-1 drug orforglipron reduced body weight more than placebo at 72 weeks in ATTAIN-J, a Japan-only Phase 3 trial in adults with obesity disease. Mean weight change was −5.9% at 6 …
Notes de l’épisode
Eli Lilly's once-daily oral GLP-1 drug orforglipron reduced body weight more than placebo at 72 weeks in ATTAIN-J, a Japan-only Phase 3 trial in adults with obesity disease. Mean weight change was −5.9% at 6 mg, −8.7% at 12 mg and −7.9% at 36 mg, versus −0.6% on placebo. At least 5% weight loss was reached by about 46%, 61% and 59% of participants on those doses, versus about 15% on placebo. Side effects were mostly mild-to-moderate gastrointestinal symptoms. The trial compared each dose with placebo and did not prove that one active dose was superior to another.
Sources
- Lancet Diabetes & Endocrinology (ATTAIN-J abstract, published online Oct 30, 2026): thelancet.com
- ClinicalTrials.gov NCT05931380 (ATTAIN-J): clinicaltrials.gov
- Grey Pepper analysis (Nov 5, 2026): greypepper.net
- Diabesity Rounds independent summary (Nov 1, 2026): diabesityrounds.com
- FDA Foundayo (orforglipron) approval announcement (Apr 1, 2026; US labeled doses differ from ATTAIN-J trial strengths): fda.gov
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Lilly's Retatrutide Beat Ozempic 2 mg on Blood Sugar and Weight Loss in Head-to-Head Diabetes Trial
Eli Lilly says its investigational once-weekly drug retatrutide beat Novo Nordisk's Ozempic 2 mg in TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide head-to-head with another incretin medicine. We …
Notes de l’épisode
Eli Lilly says its investigational once-weekly drug retatrutide beat Novo Nordisk's Ozempic 2 mg in TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide head-to-head with another incretin medicine. We walk through the topline results Lilly announced on October 28, 2026 for 1,298 adults with type 2 diabetes not controlled on metformin, with or without an SGLT2 inhibitor: at 80 weeks, A1C fell by an average of 2.2 percentage points on both retatrutide doses (9 mg and 12 mg) versus 1.8 on Ozempic 2 mg, and body weight fell 19.5% and 20.9% versus 9.4%. We explain why only the 12 mg A1C superiority result was statistically controlled while the 9 mg A1C difference was "nominal," that the figures use the efficacy estimand, and that full results have not yet been peer reviewed. We also note what Lilly said about certain cardiovascular risk factors (non-HDL cholesterol, triglycerides and systolic blood pressure) and one Leerink analyst's 2032 sales estimate, and we cover the trade-off: more gastrointestinal side effects and higher discontinuation rates due to adverse events on retatrutide (4.8% and 7.9% versus 2.7% on Ozempic). Retatrutide is not approved anywhere, and Lilly says anyone selling it to consumers is breaking the law. Sources: - Eli Lilly news release, "Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial" (Oct 28, 2026): https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more - ClinicalTrials.gov, TRANSCEND-T2D-2 (NCT06260722): https://clinicaltrials.gov/study/NCT06260722 - BioPharma Dive, "Lilly's 'triple-G' drug tops Novo's Ozempic in diabetes trial" (Oct 28, 2026): https://www.biopharmadive.com/news/retatrutide-ozempic-diabetes-trial-results-lilly-novo/873016/ - Reuters via Yahoo News, "Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial" (Oct 28, 2026): https://www.yahoo.com/news/science/articles/lillys-next-gen-drug-outshines-104705473.html Cover: original illustration made for this episode (three linked spheres beside one); no photo used. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. Visit glp1newspaper.com to see today's stories and sign up for free email alerts.Lilly Registers Two Phase 3 Trials of EloraTZP, Its Eloralintide-Tirzepatide Combination
Eli Lilly has registered two phase 3 trials of EloraTZP, an investigational once-weekly combination of the amylin agonist eloralintide and tirzepatide (the active ingredient in Zepbound and Mounjaro), on …
Notes de l’épisode
Eli Lilly has registered two phase 3 trials of EloraTZP, an investigational once-weekly combination of the amylin agonist eloralintide and tirzepatide (the active ingredient in Zepbound and Mounjaro), on ClinicalTrials.gov. We walk through how the trials are set up: AMPLIFY-1 plans to enroll about 2,115 adults with obesity and without diabetes and compares several EloraTZP doses with tirzepatide alone, eloralintide alone and placebo; AMPLIFY-2 plans to enroll about 1,000 adults with obesity or overweight and type 2 diabetes and compares EloraTZP with tirzepatide alone. Both trials measure percent change in body weight at week 100, were first posted on October 19, 2026, are not yet recruiting, and are estimated to finish in late 2029. We also recap the September 2026 phase 2b results that Lilly says led to the move (367 adults with type 2 diabetes over 48 weeks), including weight loss, A1C changes and treatment discontinuations due to side effects, and why those figures come with caveats. EloraTZP and eloralintide are investigational drugs that are not approved. Sources: - ClinicalTrials.gov, AMPLIFY-1 (NCT07881432), "A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes" (first posted Oct 19, 2026): https://clinicaltrials.gov/study/NCT07881432 - ClinicalTrials.gov, AMPLIFY-2 (NCT07881458), "A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes" (first posted Oct 19, 2026): https://clinicaltrials.gov/study/NCT07881458 - Eli Lilly news release, EloraTZP phase 2b results (Sept 30, 2026): https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide - Reuters via KSL.com, "Experimental Lilly combination drug tops Zepbound in weight-loss trial" (Sept 30, 2026): https://www.ksl.com/article/51630539/experimental-lilly-combination-drug-tops-zepbound-in--weight-loss-trial - CHOSUNBIZ, "Lilly advances amylin-based obesity combo to phase 3, tests tolerability amid Korea race" (Oct 26, 2026): https://biz.chosun.com/en/en-science/2026/10/26/VTWAF3F4D5DYTCZDOHBMIUET3A/ Cover: original abstract illustration made for this episode (two merging droplets); no photo used. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. Visit glp1newspaper.com to see today's stories and sign up for free email alerts.Lilly's Retatrutide Eased Sleep Apnea in Two Phase 3 Trials, NEJM Study Reports
Two phase 3 trials published in the New England Journal of Medicine found that Eli Lilly's investigational drug retatrutide, a once-weekly injection that acts on GIP, GLP-1 and glucagon receptors, reduced the …
Notes de l’épisode
Two phase 3 trials published in the New England Journal of Medicine found that Eli Lilly's investigational drug retatrutide, a once-weekly injection that acts on GIP, GLP-1 and glucagon receptors, reduced the severity of moderate-to-severe obstructive sleep apnea more than placebo over 80 weeks in adults with obesity or overweight. We go through the numbers from TRIUMPH-1-OSA (243 participants without type 2 diabetes) and TRIUMPH-2-OSA (448 participants with type 2 diabetes): changes in the apnea-hypopnea index and body weight compared with placebo, how many participants reached no or mild sleep apnea under the study's definition, and the side effects and treatment discontinuations reported for the two sleep apnea trials. Retatrutide is not approved and is legally available only to participants in Lilly's clinical trials, and the trials were funded by Lilly. Zepbound, by contrast, is FDA-approved for moderate-to-severe sleep apnea in adults with obesity (December 2024); the episode does not compare the two drugs. Sources: - New England Journal of Medicine, "Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea" (Grunstein et al., published Oct 20, 2026): https://www.nejm.org/doi/full/10.1056/NEJMoa2611477 - Lilly Medical, "What is the impact of retatrutide in patients with obesity or overweight and obstructive sleep apnea?" (TRIUMPH-1-OSA and TRIUMPH-2-OSA data tables): https://medical.lilly.com/us/products/answers/what-is-the-impact-of-retatrutide-in-patients-with-obesity-or-overweight-and-obstructive-sleep-apnea-447579 - Eli Lilly news release, retatrutide TRIUMPH-1 results (June 6, 2026), for retatrutide's investigational status: https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-drove-substantial-improvements - Medical Xpress, "Triple-action weekly weight-loss drug reduces sleep apnea in two late-stage trials" (Oct 24, 2026): https://medicalxpress.com/news/2026-10-triple-action-weekly-weight-loss.html - FDA, "FDA Approves First Medication for Obstructive Sleep Apnea" (Dec 20, 2024): https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea Cover photo: "CPAP mask 01" by Joe Mabel, via Wikimedia Commons, CC BY-SA 3.0 (https://commons.wikimedia.org/wiki/File:CPAP_mask_01.jpg); cropped and brightened. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. Visit glp1newspaper.com to see today's stories and sign up for free email alerts.ACOG Issues New Guidance on GLP-1 Drugs Before Pregnancy, During Pregnancy and While Breastfeeding
The American College of Obstetricians and Gynecologists (ACOG) released new guidance on October 23, 2026, on GLP-1 medications before, during and after pregnancy. The Practice Advisory tells ob-gyns to advise …
Notes de l’épisode
The American College of Obstetricians and Gynecologists (ACOG) released new guidance on October 23, 2026, on GLP-1 medications before, during and after pregnancy. The Practice Advisory tells ob-gyns to advise patients that there is not enough safety data on GLP-1 use in pregnancy, to consider stopping these medications one to two months before conception, and to advise against their use during pregnancy. For breastfeeding, ACOG says clinicians may use shared decision-making on a postpartum plan that could include GLP-1s, with close monitoring of the baby's weight gain, but recommends against use for those nursing preterm infants or newborns. We look at what the human and animal data do and do not show, why weight loss on these drugs may make pregnancy more likely, and a JAMA study linking GLP-1 discontinuation before or early in pregnancy with more gestational weight gain, part of the trade-off between stopping these drugs and the risk of weight regain. Sources: - ACOG news release, "ACOG Releases New Guidance on the Use of GLP-1s in Pregnancy and Lactation" (Oct 23, 2026): https://www.acog.org/news/2026/10/acog-releases-new-guidance-on-use-of-glp-1s-in-pregnancy-lactation/ - ACOG Practice Advisory, "Use of Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy and Lactation" (October 2026): https://www.acog.org/clinical/guidance/practice-advisory/2026/10/use-of-glucagon-like-peptide-1-receptor-agonists-in-pregnancy-and-lactation/ - JAMA, "Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation" (Maya et al., 2025): https://jamanetwork.com/journals/jama/fullarticle/2841781 Cover photo: "Silicone Baby Bottles" by TheUnaverageJoe, via Wikimedia Commons, CC BY-SA 4.0 (https://commons.wikimedia.org/wiki/File:Silicone_Baby_Bottles.jpg); cropped, embossed markings softened. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.comCompounded GLP-1 Recall and 'Research Use' Retatrutide Put Unapproved Weight-Loss Drugs Under Scrutiny
Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded tirzepatide, the active ingredient in Zepbound and Mounjaro …
Notes de l’épisode
Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded tirzepatide, the active ingredient in Zepbound and Mounjaro, citing "lack of assurance of sterility," and FDA classified the recall as Class II. A bipartisan group of senators led by Sen. Jim Banks wrote to the acting FDA commissioner on October 14, 2026, urging a crackdown on vendors using "for research use only" labels to sell retatrutide, Eli Lilly's investigational drug that is not FDA-approved, and citing a 265% rise in poisonings tied to illicit retatrutide reported by America's Poison Centers. CBS News reported that FDA received two adverse-event reports of deaths linked to products sold as retatrutide; the reports are unverified and do not prove the products caused the deaths. We also walk through FDA's own warnings: compounded drugs are not FDA-approved, retatrutide cannot be used in compounding, and FDA has flagged quality problems at overseas ingredient suppliers. We explain how compounded, counterfeit and "research use only" products differ from FDA-approved medicines, and what regulators, lawmakers and drugmakers are doing about them. Sources: - FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (updated Oct 1, 2026): https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss - Sen. Jim Banks press release and senators' letter to FDA (Oct 15, 2026): https://www.banks.senate.gov/news/press-releases/banks-urges-fda-to-crack-down-on-illicit-research-use-only-drugs/ - CBS News, reported deaths and bootleg retatrutide: https://www.cbsnews.com/news/deaths-reported-fda-bootleg-reta-weight-loss-drug/ - BioPharma Dive, Apothecary Pharma compounded tirzepatide recall (Oct 22, 2026): https://www.biopharmadive.com/news/glp1-obesity-drug-recall-apothecary-tirzepatide-zepbound/833712/ - USA TODAY, compounded GLP-1 recall and FDA actions (Oct 20, 2026): https://www.usatoday.com/story/money/personal-finance/healthcare/2026/10/20/fda-targets-copycat-glp-1-weight-loss-drugs/92343423007/ Cover photo: laboratory at the FDA White Oak campus, Building 64 (U.S. Food and Drug Administration, public domain, via Wikimedia Commons; cropped). This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.comEU Regulators Back Lilly's Foundayo Pill for Weight Loss and Type 2 Diabetes
Europe's drug regulator has recommended approval of Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) for adults, covering both weight management and type 2 diabetes. The European Medicines Agency's …
Notes de l’épisode
Europe's drug regulator has recommended approval of Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) for adults, covering both weight management and type 2 diabetes. The European Medicines Agency's human medicines committee (CHMP) adopted its positive opinion on October 15, 2026. In two weight-management studies of 4,740 adults, people taking Foundayo lost around 5% to 11% of their body weight at 72 weeks, depending on dose, compared with about 2% to 2.5% on placebo. In four type 2 diabetes studies of 3,765 adults, HbA1c fell by around 1.2 to 1.9 percentage points. The most common side effects were nausea, vomiting and diarrhoea. Unlike Novo Nordisk's Wegovy pill, which won EU approval in July for weight management only, Foundayo can be taken at any time of day with or without food. We cover what the committee looked at, what a CHMP opinion does and doesn't mean, how this fits the oral GLP-1 race between Lilly and Novo, and why the European Commission's final decision and country-by-country pricing and reimbursement still come next. Foundayo has been FDA-approved for weight management in the U.S. since April 2026. Sources: - European Medicines Agency news release (Oct 16, 2026): https://www.ema.europa.eu/en/news/new-oral-glp-1-medicine-weight-management-type-2-diabetes - EMA CHMP summary of positive opinion for Foundayo: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-foundayo_en.pdf - Fierce Pharma: https://www.fiercepharma.com/pharma/lillys-obesity-pill-revmeds-pancreatic-cancer-breakthrough-among-slew-chmp-endorsements - CNBC (Reuters): https://www.cnbc.com/2026/10/16/eli-lillys-weight-loss-pill-wins-eu-drug-regulators-backing.html - Pharmaceutical Executive: https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe Cover photo: European Medicines Agency headquarters, Amsterdam (photo © European Medicines Agency, cropped). This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.comNovo Says Women Lost 25% on CagriSema in Trial Analysis, With Differences by Menopause Stage
Novo Nordisk says women in its phase 3 REDEFINE 1 trial lost 25.0% of their body weight on average after 68 weeks on its investigational weekly injection CagriSema (cagrilintide plus semaglutide), compared with …
Notes de l’épisode
Novo Nordisk says women in its phase 3 REDEFINE 1 trial lost 25.0% of their body weight on average after 68 weeks on its investigational weekly injection CagriSema (cagrilintide plus semaglutide), compared with 3.0% on placebo, in a post hoc analysis presented at The Menopause Society 2026 Annual Meeting in San Diego. A second analysis grouped 1,902 women by menopausal stage: average weight loss was 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women, versus about 2% on placebo. Both figures use the efficacy estimand, which assumes everyone stayed on treatment, and menopause status was assigned after the fact. Novo calls the findings hypothesis-generating. We cover what the numbers do and don't show, how the full trial population compared (22.7%), how the results line up with earlier tirzepatide analyses in women, the trial's side-effect and discontinuation rates, and where CagriSema stands: not approved, with an FDA decision expected in the fourth quarter of 2026. Sources: - Novo Nordisk press release (Oct 20, 2026): https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine1-weight-loss-women-menopause.html - CNBC: https://www.cnbc.com/2026/10/20/novo-cagrisema-women-weight-loss-analysis.html - BioSpace: https://www.biospace.com/drug-development/novos-cagrisema-achieves-25-weight-loss-in-women-driven-by-younger-patients - Reuters, via ETPharma: https://pharma.economictimes.indiatimes.com/news/research-and-development/novos-cagrisema-helped-women-lose-25-of-weight-on-average-analysis-shows/135085769 Cover: original editorial image made for this episode; the pen shown is generic, not a real product. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.com
Podcasts similaires
Plus de podcasts : Forme et santé







C’est votre podcast ?
Confirmez-le avec une entrée dans votre flux : vous recevez ici un code, vous l’ajoutez comme podcast:txt dans le canal de votre flux, et nous le vérifions. Votre podcast apparaît ensuite comme « vérifié » sur SoundNode.